{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T22:32:01Z","timestamp":1774132321992,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-026-04010-0","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:02:11Z","timestamp":1770696131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy of levosimendan and dobutamine in sepsis-related cardiac impairment: a meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Xiuwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakari","family":"Shaibu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"15","key":"4010_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"JL Vincent","year":"2020","unstructured":"Vincent JL et al (2020) Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 323(15):1478\u20131487","journal-title":"JAMA"},{"key":"4010_CR2","doi-asserted-by":"publisher","first-page":"628302","DOI":"10.3389\/fmed.2021.628302","volume":"8","author":"D Jarczak","year":"2021","unstructured":"Jarczak D, Kluge S, Nierhaus A (2021) Sepsis-Pathophysiology and therapeutic concepts. Front Med (Lausanne) 8:628302","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4010_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801\u2013810","journal-title":"JAMA"},{"issue":"19","key":"4010_CR4","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2014.02.552","volume":"63","author":"F Fedele","year":"2014","unstructured":"Fedele F et al (2014) Heart failure: TNM-like classification. J Am Coll Cardiol 63(19):1959\u20131960","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4010_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13054-019-2478-6","volume":"23","author":"JL Vincent","year":"2019","unstructured":"Vincent JL et al (2019) Frequency and mortality of septic shock in Europe and North america: a systematic review and meta-analysis. Crit Care 23(1):196","journal-title":"Crit Care"},{"issue":"10219","key":"4010_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE et al (2020) Global, regional, and National sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study. Lancet 395(10219):200\u2013211","journal-title":"Lancet"},{"issue":"1","key":"4010_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13054-018-2157-z","volume":"22","author":"KE Rudd","year":"2018","unstructured":"Rudd KE et al (2018) The global burden of sepsis: barriers and potential solutions. Crit Care 22(1):232","journal-title":"Crit Care"},{"key":"4010_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijcard.2015.10.240","volume":"203","author":"P Pollesello","year":"2016","unstructured":"Pollesello P, Papp Z, Papp JG (2016) Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol 203:543\u2013548","journal-title":"Int J Cardiol"},{"issue":"5","key":"4010_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMp1707170","volume":"377","author":"K Reinhart","year":"2017","unstructured":"Reinhart K et al (2017) Recognizing sepsis as a global health Priority - A WHO resolution. N Engl J Med 377(5):414\u2013417","journal-title":"N Engl J Med"},{"issue":"10141","key":"4010_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","volume":"392","author":"M Cecconi","year":"2018","unstructured":"Cecconi M et al (2018) Sepsis and septic shock. Lancet 392(10141):75\u201387","journal-title":"Lancet"},{"issue":"7","key":"4010_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","volume":"17","author":"T van der Poll","year":"2017","unstructured":"van der Poll T et al (2017) The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 17(7):407\u2013420","journal-title":"Nat Rev Immunol"},{"issue":"9328","key":"4010_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(02)09459-X","volume":"360","author":"D Brealey","year":"2002","unstructured":"Brealey D et al (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360(9328):219\u2013223","journal-title":"Lancet"},{"issue":"6","key":"4010_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","volume":"18","author":"SM Hollenberg","year":"2021","unstructured":"Hollenberg SM, Singer M (2021) Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol 18(6):424\u2013434","journal-title":"Nat Rev Cardiol"},{"key":"4010_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D et al (2016) Levosimendan beyond Inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol 222:303\u2013312","journal-title":"Int J Cardiol"},{"issue":"4","key":"4010_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10741-008-9128-4","volume":"14","author":"JT Parissis","year":"2009","unstructured":"Parissis JT et al (2009) Levosimendan: from basic science to clinical practice. Heart Fail Rev 14(4):265\u2013275","journal-title":"Heart Fail Rev"},{"key":"4010_CR16","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS et al (2016) Sepsis and septic shock. Nat Rev Dis Primers 2:16045","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"4010_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47(11):1181\u20131247","journal-title":"Intensive Care Med"},{"issue":"5","key":"4010_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00134-005-2619-z","volume":"31","author":"A Morelli","year":"2005","unstructured":"Morelli A et al (2005) Effects of Levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31(5):638\u2013644","journal-title":"Intensive Care Med"},{"issue":"9","key":"4010_CR19","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1097\/01.CCM.0000230244.17174.4F","volume":"34","author":"A Morelli","year":"2006","unstructured":"Morelli A et al (2006) Effects of Levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 34(9):2287\u20132293","journal-title":"Crit Care Med"},{"issue":"5","key":"4010_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11886-020-01277-2","volume":"22","author":"M L\u2019Heureux","year":"2020","unstructured":"L\u2019Heureux M et al (2020) Sepsis-Induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep 22(5):35","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"4010_CR21","doi-asserted-by":"publisher","first-page":"e019338","DOI":"10.1136\/bmjopen-2017-019338","volume":"8","author":"W Chang","year":"2018","unstructured":"Chang W et al (2018) Effect of Levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials. BMJ Open 8(3):e019338","journal-title":"BMJ Open"},{"issue":"17","key":"4010_CR22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","volume":"375","author":"AC Gordon","year":"2016","unstructured":"Gordon AC et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375(17):1638\u20131648","journal-title":"N Engl J Med"},{"issue":"5","key":"4010_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jcrc.2015.05.017","volume":"30","author":"A Zangrillo","year":"2015","unstructured":"Zangrillo A et al (2015) Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. J Crit Care 30(5):908\u2013913","journal-title":"J Crit Care"},{"issue":"11","key":"4010_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029092","volume":"101","author":"J Guo","year":"2022","unstructured":"Guo J, Zhang X, Zhu Y, Cheng Q (2022) Comparison of Dobutamine and Levosimendan for treatment of sepsis-induced cardiac dysfunction: A protocol for systematic review and meta-analysis. Med (Baltim) 101(11):e29092. https:\/\/doi.org\/10.1097\/MD.0000000000029092","journal-title":"Med (Baltim)"},{"issue":"1","key":"4010_CR25","doi-asserted-by":"publisher","first-page":"20333","DOI":"10.1038\/s41598-021-99716-9","volume":"11","author":"DH Liu","year":"2021","unstructured":"Liu DH et al (2021) Levosimendan versus Dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis. Sci Rep 11(1):20333","journal-title":"Sci Rep"},{"issue":"8","key":"4010_CR26","first-page":"668","volume":"29","author":"Z Ma","year":"2023","unstructured":"Ma Z et al (2023) A Meta-Analysis of the effects of Levosimendan on cardiac function and outcomes in patients with sepsis. Altern Ther Health Med 29(8):668\u2013673","journal-title":"Altern Ther Health Med"},{"key":"4010_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-physiol-061121-040214","volume":"84","author":"LK Torres","year":"2022","unstructured":"Torres LK, Pickkers P, van der Poll T (2022) Sepsis-Induced Immunosuppression Annu Rev Physiol 84:157\u2013181","journal-title":"Sepsis-Induced Immunosuppression Annu Rev Physiol"},{"key":"4010_CR28","doi-asserted-by":"publisher","first-page":"1641604","DOI":"10.3389\/fcvm.2025.1641604","volume":"12","author":"F Zhao","year":"2025","unstructured":"Zhao F et al (2025) Levosimendan versus Dobutamine in septic cardiomyopathy: a randomized clinical trial on cardiac function and safety. Front Cardiovasc Med 12:1641604","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"4010_CR29","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","volume":"45","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB et al (2019) Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the leopards randomised trial. Intensive Care Med 45(10):1392\u20131400","journal-title":"Intensive Care Med"},{"issue":"6","key":"4010_CR30","doi-asserted-by":"publisher","first-page":"R232","DOI":"10.1186\/cc9387","volume":"14","author":"A Morelli","year":"2010","unstructured":"Morelli A et al (2010) Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 14(6):R232","journal-title":"Crit Care"},{"key":"4010_CR31","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.12659\/MSM.898457","volume":"22","author":"JB Meng","year":"2016","unstructured":"Meng JB et al (2016) Levosimendan versus Dobutamine in myocardial injury patients with septic shock: A randomized controlled trial. Med Sci Monit 22:1486\u20131496","journal-title":"Med Sci Monit"},{"issue":"3","key":"4010_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SHK.0000000000000851","volume":"48","author":"Z Hajjej","year":"2017","unstructured":"Hajjej Z et al (2017) Effects of Levosimendan on cellular metabolic alterations in patients with septic shock: A randomized controlled pilot study. Shock 48(3):307\u2013312","journal-title":"Shock"},{"issue":"6","key":"4010_CR33","first-page":"423","volume":"57","author":"CX Xu","year":"2018","unstructured":"Xu CX et al (2018) [The effects of Levosimendan on the cardiac function and prognosis in elderly patients with septic shock and myocardial contractility impairment]. Zhonghua Nei Ke Za Zhi 57(6):423\u2013428","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"3","key":"4010_CR34","doi-asserted-by":"publisher","first-page":"318e1","DOI":"10.1016\/j.jcrc.2011.06.008","volume":"27","author":"D Memi\u015f","year":"2012","unstructured":"Memi\u015f D, Inal MT, Sut N (2012) The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. J Crit Care 27(3):318e1-318e6","journal-title":"J Crit Care"},{"issue":"6","key":"4010_CR35","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/life13061346","volume":"13","author":"V Tsolaki","year":"2023","unstructured":"Tsolaki V et al (2023) Levosimendan in the treatment of patients with severe septic cardiomyopathy. Life 13(6):1346","journal-title":"Life"},{"issue":"3","key":"4010_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.jvca.2022.10.032","volume":"37","author":"T Sun","year":"2023","unstructured":"Sun T et al (2023) Efficacy of Levosimendan in the treatment of patients with severe septic cardiomyopathy. J Cardiothorac Vasc Anesth 37(3):344\u2013349","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"11","key":"4010_CR37","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"17","key":"4010_CR38","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A et al (2007) Levosimendan vs Dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297(17):1883\u20131891","journal-title":"JAMA"},{"issue":"1","key":"4010_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s13054-019-2674-4","volume":"23","author":"B Cholley","year":"2019","unstructured":"Cholley B et al (2019) Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 23(1):385","journal-title":"Crit Care"},{"issue":"4","key":"4010_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jcrc.2014.03.028","volume":"29","author":"E Antonucci","year":"2014","unstructured":"Antonucci E et al (2014) Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care 29(4):500\u2013511","journal-title":"J Crit Care"},{"issue":"7","key":"4010_CR41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/eurheartj\/ehr351","volume":"33","author":"G Landesberg","year":"2012","unstructured":"Landesberg G et al (2012) Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 33(7):895\u2013903","journal-title":"Eur Heart J"},{"issue":"3","key":"4010_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43(3):304\u2013377","journal-title":"Intensive Care Med"},{"issue":"2","key":"4010_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of Levosimendan. Int J Cardiol 159(2):82\u201387","journal-title":"Int J Cardiol"},{"issue":"4","key":"4010_CR44","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/cc10307","volume":"15","author":"J Hasslacher","year":"2011","unstructured":"Hasslacher J et al (2011) Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care 15(4):R166","journal-title":"Crit Care"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04010-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:02:13Z","timestamp":1773313333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4010"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04010-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}